# Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control

> **NCT02913794** · — · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 541 (actual)

## Conditions studied

- Cardiovascular Diseases
- Hyperlipidemias

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02913794
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-11
- **Primary completion:** 2018-03-29
- **Final completion:** 2018-03-29
- **Target enrollment:** 541 (ACTUAL)
- **Last updated:** 2023-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02913794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02913794, "Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02913794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*